` SAGE (SAGE Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

SAGE
vs
S&P 500

Over the past 12 months, SAGE has significantly outperformed S&P 500, delivering a return of +74% compared to the S&P 500's +16% growth.

Stocks Performance
SAGE vs S&P 500

Loading
SAGE
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SAGE vs S&P 500

Performance Gap Between SAGE and GSPC
HIDDEN
Show

Performance By Year
SAGE vs S&P 500

Loading
SAGE
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
SAGE Therapeutics Inc vs Peers

S&P 500
SAGE
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

SAGE Therapeutics Inc
Glance View

Market Cap
543.6m USD
Industry
Biotechnology

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2014-07-18. The firm's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. The company has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. The company targets diseases and disorders of the brain with three focus areas: depression, neurology and neuropsychiatry. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Zuranolone is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. The company has a portfolio of other compounds that target GABAA receptors, including SAGE-324.

SAGE Intrinsic Value
HIDDEN
Show
Back to Top